Raymond James & Associates Puma Biotechnology, Inc. Transaction History

Raymond James & Associates

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$7.78 - $12.13 $85,580 - $133,430	-11,000 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$9.5 - $11.14 $104,500 - $122,540	11,000 New	11,000 $111,000
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $316,951 - $460,426	-7,693 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $159,534 - $225,429	3,303 Added 75.24%	7,693 $455,000
Q1 2018 May 14, 2018	BUY	$59.7 - $99.25 $8,358 - $13,895	140 Added 3.29%	4,390 $299,000
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $398,862 - $562,912	4,250	4,250 $420,000

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $143M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.